Advertisement


Elizabeth R. Plimack, MD, on Bladder Cancer Highlights From the 2021 Genitourinary Cancers Symposium

2021 Genitourinary Cancers Symposium

Advertisement

Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses key abstracts discussed at this year’s meeting on bladder cancer and offers her views on the latest trends and findings (Abstracts 391, 393, 434).



Related Videos

Kidney Cancer

Sumanta K. Pal, MD, on Advanced RCC: Tivozanib to Treat Disease Progression After Axitinib

Sumanta K. Pal, MD, of City of Hope, discusses findings of the TIVO-3 study, which showed that the tyrosine kinase inhibitor tivozanib improved progression-free survival vs sorafenib in patients whose advanced renal cell carcinoma progressed after multiple lines of therapy (Abstract 278).

Prostate Cancer

Neeraj Agarwal, MD, on Prostate Cancer: Apalutamide vs Placebo in Treatment of Metastatic Disease

Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses final results of the phase III TITAN study, which showed apalutamide plus androgen-deprivation therapy improved overall survival, reducing the risk of death up to 48%. This combination treatment also delayed castration resistance and maintained health-related quality of life for patients with metastatic castration-sensitive prostate cancer (Abstract 11).

Kidney Cancer
Immunotherapy

Elizabeth R. Plimack, MD, on RCC: Outcomes With Pembrolizumab Plus Axitinib

Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses phase III results from the KEYNOTE-426 study—specifically, an exploratory subgroup analysis of patients with advanced renal cell carcinoma who were randomly assigned to receive pembrolizumab plus axitinib and completed 2 years of treatment (Abstract 327).

Bladder Cancer
Kidney Cancer
Prostate Cancer

Christopher Sweeney, MBBS, and Thomas Powles, MD, PhD, on Treating GU Malignancies: Expert Views

A spirited discussion ensued when we asked Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, to compare notes on how they treat bladder, prostate, and kidney cancers.

Bladder Cancer
Immunotherapy

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Enfortumab Vedotin-ejfv vs Chemotherapy

Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, discusses phase III results from the EV-301 trial, which showed that enfortumab vedotin is the first therapy to demonstrate a significant survival advantage over standard chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma (Abstract 393).

Advertisement

Advertisement




Advertisement